← Back to Search

Norepinephrine-Dopamine Reuptake Inhibitor

Centanafadine for ADHD

Phase 3
Recruiting
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females aged 4 to 17 years (inclusive) at the time of informed consent/assent.
A primary diagnosis of ADHD based on DSM-5 diagnosis criteria as confirmed with the MINI-KID (for children and adolescents aged 4 to 17 years [inclusive]).
Must not have
Subjects who are breast-feeding and/or have a positive pregnancy test result prior to receiving IMP.
Body weight < 13 kg
Timeline
Screening 3 weeks
Treatment Varies
Follow Up minimum duration of 52 weeks, up to a maximum of approximately 136 weeks or early termination.
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.

Who is the study for?
This trial is for children and adolescents aged 4 to 17 with ADHD who completed a previous double-blind study. They must have an ADHD diagnosis, significant symptoms, and in some cases, inadequate response to psychotherapy. Excluded are those with certain severe psychiatric conditions or history of drug-related skin reactions.
What is being tested?
The trial tests the long-term safety of Centanafadine Hydrochloride, taken once daily as an extended-release (XR) medication for treating ADHD in pediatric patients. It follows up on participants from a prior study to assess tolerability over a longer period.
What are the potential side effects?
While specific side effects aren't listed here, the focus is on evaluating any adverse reactions related to skin health due to past drug exposure and overall tolerability issues that may arise during prolonged use of Centanafadine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 4 and 17 years old.
Select...
I have been diagnosed with ADHD according to DSM-5 criteria.
Select...
My ADHD symptoms score is 28 or higher.
Select...
I am between 4 and 17 years old.
Select...
I have been diagnosed with ADHD according to DSM-5 criteria.
Select...
My ADHD symptoms score is 28 or higher.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
My body weight is less than 13 kg.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~minimum duration of 52 weeks, up to a maximum of approximately 136 weeks or early termination.
This trial's timeline: 3 weeks for screening, Varies for treatment, and minimum duration of 52 weeks, up to a maximum of approximately 136 weeks or early termination. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine long-term safety and tolerability of Centanafadine QD XR Capsules.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Centanafadine HydrochlorideExperimental Treatment1 Intervention
Adolescents (13 to 17 years of age, inclusive) to receive 328.8 mg daily. Children (4 to 12 years of age, inclusive) will receive weight-based doses of centanafadine ranging from 82.2 mg to 328.8 mg daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Centanafadine Hydrochloride
2022
Completed Phase 3
~460

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ADHD primarily include stimulant medications such as methylphenidate and amphetamines, which increase the levels of dopamine and norepinephrine in the brain, enhancing attention and reducing impulsivity and hyperactivity. Non-stimulant options like atomoxetine work by selectively inhibiting the reuptake of norepinephrine, thereby improving focus and behavior. Alpha-2 adrenergic agonists like guanfacine modulate noradrenergic tone, which can help with hyperactivity and impulsivity. Centanafadine, a triple reuptake inhibitor, increases the levels of norepinephrine, dopamine, and serotonin, potentially offering a broader spectrum of symptom control. These mechanisms are crucial for ADHD patients as they target the neurochemical imbalances associated with the disorder, thereby improving cognitive function and behavioral outcomes.
Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies.

Find a Location

Who is running the clinical trial?

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
264 Previous Clinical Trials
169,379 Total Patients Enrolled
10 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
3,779 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

Centanafadine Hydrochloride (Norepinephrine-Dopamine Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05279313 — Phase 3
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Centanafadine Hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Centanafadine Hydrochloride Highlights & Side Effects. Trial Name: NCT05279313 — Phase 3
Centanafadine Hydrochloride (Norepinephrine-Dopamine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05279313 — Phase 3
~0 spots leftby Nov 2024